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Abstract
Introduction. Cervical cancer is a leading cause of mortality in women worldwide. The resistance to irradiation 
at the advanced stage is the main reason for the poor prognosis and high mortality. This work aims to elucidate 
the molecular mechanism underlying the radio-resistance.
Material and methods. In this study, we determined the pEGFR-T654 and pDNA-PK-T2609 expression level 
changes in irradiated HeLa cells treated with T654 peptide, a nuclear localization signal (NLS) inhibitor, to 
inhibit EGFR nuclear transport. Cell viability, cell cycle and migratory capacity were analyzed. Xenograft an-
imal model was used to evaluate the effect of EGFR nuclear transport inhibition on the tumor growth in vivo.
Results. The enhanced translocation of nuclear EGFR in the irradiated HeLa cells correlated with the increasing 
level of pEGFR-T654 and pDNA-PK-T2609. Inhibition of EGFR nuclear translocation by NLS peptide inhibitor 
attenuated DNA damage repair in the irradiated HeLa cells, decreased cell viability and promoted cell death 
through arrest at G0 phase. NLS peptide inhibitor impaired the migratory capacity of irradiated HeLa cells, and 
negatively affected tumorigenesis in xenograft mice.
Conclusions. This work puts forward a potential molecular mechanism of the irradiation resistance in cervical 
cancer cells, providing a promising direction towards an efficient therapy of cervical cancer. (Folia Histochemica 
et Cytobiologica 2017, Vol. 55, No. 2, 43–51)
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Introduction
Cervical cancer is the leading cause of cancer-associ-
ated mortality in women [1]. Although the great pro-
gress has been made in the diagnosis and treatment of 
cervical cancer, the five year survival rate is still low 
due to the tumor metastasis and drug resistance [2]. 
One of the most commonly used treatments for 
cervical cancer is radiotherapy. However, radiation 
resistance causes inefficiency of irradiation therapy, 
especially in the patients at advanced stage. There-
fore, resistance to radiation is considered as a poor 
indicator to prognosis [3]. 
In order to clarify the underlying mechanism of ra-
diation resistance, several studies indicated the critical 
genes involved in the process of radio-resistance [4–8]. 
Most recently, it has been reported that mutation in 
epidermal growth factor receptor (EGFR) correlat-
ed with the results of cervical cancer treatment [9]. 
EGFR is one of four members of the ErbB family of 
receptor tyrosine kinases. The nuclear translocation 
of EFGR was reported to be involved in the resistance 
to cancer therapy [12, 13]. Nuclear localization signal 
(NLS) of EGFR that plays a critical role in the nuclear 
translocation [15] has been considered as a key factor 
to the resistance to cancer therapy [13]. However, 
the function of the nuclear translocation of EGFR in 
cervical cancer has not been well studied.
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In the current study, we elucidated the role of 
EGFR nuclear translocation in the radiosensitivity 
of cervical cancer cells. We found that inhibition of 
nuclear translocation could decrease the survival 
rate and attenuate the migration capacity of cervical 
cancer cells after irradiation. It also reduced tumori-
genesis in xenograft nude mice models in vivo. 
Material and methods
Cell culture and irradiation exposure. HeLa cell line was 
purchased from ATCC (Manassas, VA, USA). The cultures 
were maintained in DMEM supplemented with 10% fetal 
bovine serum (Life Technologies, Carlsbad, CA, USA). The 
cells were grown at 37°C in a humidified incubator in an at-
mosphere of 5% CO2 and passaged every 3 days. Cells were 
exposed to a single dose of 4 Gy of X-rays using the 200-kV 
photons linear accelerator (Gulmay RS 225, Byfleet, UK) at 
a dose rate of 450 cGy/min for 40 min at 37°C.
Construction of EGFP-C1-EGFR plasmid and establish-
ment of EGFR-overexpressed cell line. Human full length 
EGFR cDNA was ligated into EGFR-C1 plasmid. The 
insertion was confirmed by sequencing. The EGFR plas-
mid was transfected into Hela cells by Lipofectamine 2000 
(Life Technologies). The cells stably expressing EGFR 
was selected by neomycin. The overexpression of EGFR in 
selected cell lines was confirmed by GFP fluorescence and 
immunoblotting against EGFR. 
Western blot. 2 μg of cell lysates were loaded on each lane 
of 10% polyacrylamide gel, and then blotted onto a poly-
vinylidene difluoride (PVDF) membrane. After blocking 
with a PBST (phosphate-buffered saline containing 0.3% 
Trition-X100) containing 5% nonfat dry milk, the membrane 
was incubated with antibodies against EGFR, phosphoryl-
ated EGFR at T654 (p-EGFR-T654), and phosphorylated 
DNA-PK at T2609 (p-DNA-PK-T2609) (Cell Signaling 
Technologies, MA, USA). Peroxidase-linked anti rabbit IgG 
(Life Technologies) were used as secondary antibodies. These 
proteins were visualized by using an ECL Western blotting 
detection kit (Amersham Biosciences, Little Chalfont, UK).
Subcellular fractionation. Cytoplasmic and nuclear extracts 
were prepared according to the instructions of the NE-PER® 
nuclear and cytoplasmic extraction kit (Pierce, Rockford, 
IL, USA).
T654-peptide and control peptide. T654-peptide (EGFR 
NLS peptide inhibitor RKRT(PO3H2)LRRLK) and control 
peptide (KKALRRQEAVNAL) were synthesized by GL 
Biochem (Shanghai, China). Cells were treated with 5 μM 
peptide for 12 hours. The function of inhibitor and control 
peptides was confirmed in the previous report [16]. 
Cell viability assessment. MTT assay was used to de-
tect effect of T654-peptide on cell viability of irradiated 
HeLa. Briefly, MTT also known as 3-(4,5-dimethylthi-
azol-2-yl)-2,5-diphenyltetrazolium bromide (Sangon Bio-
tech, Shanghai, China) was incubated with cells for 4 hrs to 
produce formazan salts. When formazan was completely dis-
solved by SDS-HCl, the absorbance at 570 nm was measured 
with a Universal Microplate Reader (Bio-Tek Instruments, 
Winooski, VT, USA), and the ratio of the optical density 
(OD) of sample group/OD of blank control was calculated. 
TUNEL assay. Terminal deoxynucleotidyl transferase- 
-mediated dUTP nick end labeling (TUNEL) assay was 
performed by using an in situ cell death detection kit 
(Santa Cruz Biotechnology, Dallas, TX, USA). Briefly, 
thyroid sections were fixed with 4% paraformaldehyde 
and permeabilized with 0.2% Triton X-100. Fragmented 
DNA was labeled with fluorescein-12-dUTP at 37°C for 
1 hour. TUNEL-positive nuclei were detected with Eclipse 
E1000 fluorescent microscope (Nikon, Tokyo, Japan).
Immunohistochemistry. The sections of xenograft tumors 
were washed in PBS, blocked for 60 min in 0.3% Triton 
X-100 in PBS with 5% bovine serum albumin, and then incu-
bated at 4°C with anti-Ki67 antibodies (Abcam, Cambridge, 
UK) overnight. FITC-conjugated secondary antibody was 
used to visualize the positive cells. Ratio of Ki67-positive 
cell was measured by Nikon Eclipse E1000 fluorescent 
microscope.
RNA extraction and qRT-PCR. Total RNA extraction 
was performed using TRIzol reagent (Life Technologies) 
according to the manufacturer’s instruction. Two micro-
grams of total RNA extracted from the cells was subjected 
to reverse transcription (RT). Synthesis of cDNA was per-
formed by using one-step RT-PCR kit from Takara (Dalian, 
China). SYBR Green (Toyobo, Osaka, Japan) RT-PCR 
amplification and real time fluorescence detection were 
performed using ABI 7300 real-time PCR thermal cycle 
instrument (ABI, Foster City, CA, USA), according to the 
supplied protocol. Relative gene expression was calculated 
by the ∆∆Ct method. Primers used for Ki67 are as follows: 
5’-ATAAACACCCCAACACACACAA-3’ and 5’-GC-
CACTTCTTCATCCAGTTAC-3’. The relative expression 
levels were normalized to the expression of endogenous 
GAPDH (5’-GGTATCGTGGAAGGACTCATGAC-3’ and 
5’-ATGCCAGTGAGCTTCCCGT TCAGC-3’).
Xenograft tumor models. BALB/c nude mice were pur-
chased from Shanghai Lab Animal Research Center (Shang-
hai, China). All the animal handling was conformed to the 
protocols approved by the Institutional Animal Care and 
Use Committee of Weifang Hospital of Traditional Chinese 
Medicine. According to previous study [17], inoculation 
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area of the mice was cleaned and sterilized with ethanol 
and iodine solutions. 1 × 105 irradiated HeLa cells in PBS 
treated by a control peptide (a peptide with the scramble 
amino acid sequence similar with T654-peptide but with-
out the biological function) or T654-peptide were injected 
subcutaneously into the right flank of 6 weeks-old BALB/c 
nude mice. Each group contained six mice, and xenograft 
experiments were conducted in triplicate. Obvious tumor 
was observed 4 weeks after cell injection. The implanted 
mice were observed daily until 60 days. Tumor volume (V) 
was calculated using the following equation: Tumor volume 
(mm3) = 0.5 × length × width2.
Analysis of cell cycle phase by flow cytometry. Twelve hours 
following the treatment with control peptide or T654 pep-
tide, the HeLa cells were resuspended in PBS twice before 
fixation by adding dropwise into to 95% precooled ethanol. 
Prior to analysis, the cells were warmed, centrifuged at 450 g 
for 5 min and resuspended twice in PBS, then stained with 
propidium iodide containing RNase A at 50 μg/mL (San-
gon, Shanghai, China) at room temperature in the dark for 
30 min. The DNA content was analyzed by flow cytometry 
using the CellQuest program (Becton-Dickinson, Franklin 
Lakes, NJ, USA).
Scratch wound assay. Cells were seeded on 60 cm2 tis-
sue-culture plastic dishes at 80% cell confluence. A scratch 
wound was performed using a sterile 200 μL pipette tip. 
Phase-contrast images were taken at different time points. 
The distance between the scratch line and the number of 
cells which crossed the scratch line were measured. 
Statistical analysis. For statistical analysis, all data were 
obtained from three independent experiments. Data were 
presented as mean ± SEM. The band density in the West-
ern blot analysis was measured by using Image J software 
(developed at the National Institutes of Health, Bethesda, 
MD, USA). Unpaired Student’s t-test was used to deter-
mine significant differences. A p value less than 0.05 was 
considered as significantly different.
Results
Radiation induced the phosphorylation of EGFR  
at Thr654
Firstly, we elucidated whether the EGFR nuclear 
translocation could affect the proliferation of cervical 
cancer cells. The overexpression of EGFR led to the in-
creased level of nuclear EGFR in HeLa cells (Fig. 1A). 
The nuclear accumulation of EFGR in HeLa cells 
was associated with enhanced proliferation after 
exposure to irradiation (Fig. 1B, p < 0.05). Then, we 
determined whether the radiation could affect the 
expression of EGFR in the nucleus (nEGFR) of HeLa 
cells. The nEGFR level was significantly increased 
after irradiation, indicating the initiation of nuclear 
transport of EGFR evoked by irradiation (Fig. 2A, B). 
Meanwhile, the phosphorylation of EGFR at Thr654 
Figure 1. The effects of the epithelial growth factor receptor (EGFR) overexpression in HeLa cells on the level of nuclear 
EGFR (nEGFR) (A) and cell proliferation (B). Overexpression of EGFR enhanced proliferation when HeLa cells were 
exposed to irradiation (n = 801 cells from three independent preparation). The way of overexpressing EGFR was described 
in Material and methods.
BA
46 Hong Wei et al.
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2017
10.5603/FHC.a2017.0007
www.fhc.viamedica.pl
(pEGFR-T654) was drastically increased at 40 min 
after exposure to radiation (Fig. 2A, B). Enhanced 
pEGFR-T654 was accompanied by the increased 
phosphorylation level of DNA-PK at T2609 (p-DNA- 
-PK-T2609), which showed that elevated pEG-
FR-T654 level after radiation correlated with DNA 
repair (Fig. 2A, B). We did not observe any alterations 
in pEGFR-T654 and p-DNA-PK-T2609 levels in the 
presence of p-Tyr, indicating the direct correlation 
between pEGFR-T654 and p-DNA-PK-T2609. 
Collectively, these data demonstrated that exposure 
of the HeLa cells to irradiation led to the increased 
phosphorylation level of EGFR at Thr654, which sub-
sequently induced increased p-DNA-PK-T2609 level. 
Inhibitory effect of T654-peptide  
on the phosphorylation of DNA-PK
Next, we used T654-peptide to inhibit the EGFR trans-
port in HeLa cells. We found that T654-peptide could 
prevent the nuclear translocation of EGFR induced 
by radiation. No significantly enhanced expression 
of nuclear EGFR was observed in radiation-exposed 
HeLa cells when treated with T654-peptide (Fig. 3). 
The phosphorylation of EGFR was also inhibited after 
Figure 2. The effects of irradiation on the characteristics of control and modified HeLa cells. A. Western blotting analysis 
indicated that EGFR expression in nuclei of HeLa cells was increased when exposed to irradiation for 40 min. The phos-
phorylation of EGFR at Thr654 (p-EGFR-T654) and of DNA-dependent protein kinase at Thr2609 (p-DNA-PK-T2609) 
showed the similar pattern; B. The increase in EGFR, p-EGFR-T654, and p-DNA-PK-T2609 level of irradiated HeLa 
cells was significantly different from the untreated control; unpaired Student’s t test; **p < 0.01 and ***p < 0.001; 
C, D. Treatment of ortho-phospho-L-tyrosine (p-Tyr) treatment did not alter the level of p-EGFR and p-DNA-PK in HeLa 
cells; ns — not significant.
BA
DC
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treatment with T654-peptide (Fig. 3). Furthermore, 
we did not found increased phosphorylation level of 
DNA-PK at T2609 in the presence of T654-peptide. 
This suggested that nuclear translocation of EGFR 
was important to the DNA repair in HeLa cells after 
exposure to irradiation. 
654-peptide enhanced HeLa cell death after radiation
To further validate the effect of T654-peptide on the 
irradiated HeLa cells, we measured cell proliferation 
and death. The MTT assay showed that the cell via-
bility was significantly lower after irradiation in the 
presence of T654-peptide, compared to the cells treat-
ed with control peptide (Fig. 4A). Cell death was also 
affected by the T654-peptide. The results of TUNEL 
assay showed that more dead cells were observed in 
T654-peptide-treated group (Fig. 4C) than in control 
peptide-treated cells (Fig. 4B). The percentage of 
TUNEL-positive cells drastically increased by 106 ± 
± 30% in HeLa cells treated with T654-peptide com-
pared to the control peptide-treated cells (Fig. 4D). 
Furthermore, to investigate the specific effect of 
T654-peptide on HeLa cells, we treated EGF-non-
responsive rat cell N-3 with T654-peptide and found 
that T654-peptide did not alter N-3 cell proliferation 
(Fig. 4E). Also, we did not observe any significant 
change in the level of p-DNA-PK T2609 (Fig. 4F), 
demonstrating that T654-peptide treatment did not 
influence DNA repair. These data demonstrated that 
inhibition of EGFR nuclear translocation promoted 
the death of HeLa cell after irradiation. 
T654-peptide led to the G0 arrest  
in irradiated HeLa cells
Further, we determined by flow cytometry whether 
the T654-peptide treatment could affect the cell cycle 
of irradiated HeLa cells. Compared to the irradiated 
HeLa cells treated with control peptide, the ratio of 
cells at G0/G1 phase significantly increased by 123 ± 
24% in cells treated with T654-peptide (Fig. 5). By 
contrast, the ratio of cells at G2/M phases was drasti-
cally decreased by 27 ± 4% in T654-peptide-treated 
irradiated cells. We did not observe any significant 
alteration in the ratio of cells at the S phase (Fig. 5). 
This finding indicated that inhibition of EGFR 
nuclear translocation could prevent their radiated 
cells from entering the cell cycle, and then affect cell 
viability and induce cell death. 
T654-peptide inhibited the migratory ability  
of irradiated HeLa cells
Next, we determined whether T654-peptide treatment 
could affect the migratory ability of HeLa cells after 
irradiation. The scratch wound assay showed that the 
scratch distance in T654-peptide treated HeLa cells 
increased by 98 ± 16% compared to the control pep-
Figure 3A. Inhibition of EGFR nuclear translocation by T654-peptide treatment inhibited the increase in epithelial growth 
factor receptor (EGFR), phosphorylation of EGFR (p-EGFR), and phosphorylation of DNA-dependent protein kinase 
(p-DNA-PK) levels induced by the irradiation of HeLa cells; B. Statistical analysis showed that T654-peptide treatment 
significantly decreased irradiation-evoked increase in EGFR, p-EGFR, and p-DNA-PK levels compared to the cells treated 
with control peptide. Unpaired Student’s t test; **p < 0.01; ***p < 0.001.
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tide-treated cells (Fig. 6A–C). We also found that the 
number of cells that cross the scratch line decreased 
by 54 ± 12% with the treatment with T654-peptide 
(Fig. 6D). These data showed that inhibition of EGFR 
nuclear translocation could negatively regulate migra-
tory capacity in irradiated HeLa cells. 
Tumorigenesis of T654-peptide-treated  
HeLa cells in vivo 
Finally, we investigated the effect of T654-peptide 
on tumorigenesis of irradiated HeLa cells in vivo. 
Xenograft experiment showed that incubation of 
T654-peptide with the irradiated HeLa cells reduced 
the capacity of tumorigenesis in BALB/c nude mice 
(Fig. 7A). Compared to the control peptide-treat-
ed cells, the size was significantly reduced by 55 ± 
11%, 51 ± 10%, and 49 ± 7% in tumors formed by 
T654-peptide-treated cells at the 30th, 40th, and 50th 
day after cell graft, respectively (Fig. 7B). Besides, 
the mRNA level of Ki67 in tumor formed by cells 
treated with T654-peptide was lower by 52 ± 7% 
than in tumor formed by cells treated with control 
peptide (Fig. 7C). Immunostaining provided similar 
result since we found that the ratio of Ki67+ cells was 
lower by 48 ± 6% in tumor formed by cells treated 
Figure 4. MTT assay showed that the viability of irradiated HeLa cells was negatively affected when treated with T654-peptide 
(A). More TUNEL+ cells were observed in T654-peptide-treated group (C) compared to the control peptide-treated cells 
(B). The difference in TUNEL+ cells between HeLa cells treated with T654 (n = 774 cells from three independent prepa-
ration) or control peptide (n = 695 cells from three independent preparation) was statistically significant (D). T654-peptide 
treatment did not affect the proliferation of N-3 cells (E) or the phosphorylation level of DNA-dependent protein kinase 
(p-DNA-PK) (F). Unpaired Student’s t test; ns — not significant; **p < 0.01. Scale bar represents 20 μm. 
Figure 5. Cell cycle analysis showed the ratio of the HeLa cells 
at G0/G1 stage was increased in the presence of T654-peptide 
in contrast to the cells treated with control peptide, while 
the ratio of cells at G2/M stage was decreased. Unpaired 
Student’s t test; ns — not significant; *p < 0.05; **p < 0.01.
BA D
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with T654-peptide (Fig. 7D). This in vivo study further 
indicated that the inhibition of EGFR nuclear trans-
location negatively regulated the HeLa cell growth 
and proliferation after irradiation.
Discussion
In this study, we elucidated the role of EGFR nuclear 
shuttling in radiation resistance of HeLa cells. Our 
Figure 7. T654-peptide treatment of HeLa cells decreased tumor growth in vivo. A. Different size of tumor formed by control 
peptide treated cells (upper image) and T654-peptide treated cells (lower image); B. Significant decrease of tumor size after 
transplantation of cells treated with T654-peptide; C. The mRNA level of Ki67 was decreased in tumor formed by T654-pep-
tide-treated cells; D. The ratio of Ki67+ cells was decreased in tumor formed by T654-peptide-treated cells after irradiation 
compared to the tumor formed by irradiated cells treated with control peptide. Unpaired Student’s t test; **p < 0.01.
Figure 6. Images show the difference in the migration between T654-peptide-treated HeLa cells (A) and cells treated with 
control peptide (B). Statistical analysis showed that the distance between scratch line was significantly lower in irradiated HeLa 
cells treated with T654-peptide (C). The number of migratory cells crossing the scratch line was decreased in the presence 
of cells treated with T654-peptide compared to the control peptide-treated cells (D). Unpaired Student’s t test; **p < 0.01.
BA
DC
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findings showed that inhibition of EGFR nuclear 
translocation has weakened the resistance to irradia-
tion, reduced cell viability in vitro and attenuated the 
tumorigenesis in vivo. This is an important piece of 
evidence to support the potential clinical application 
of EGFR NLS peptide inhibitor in the treatment of 
cervical cancer. 
It is well known that EGFR phosphorylation was 
a critical step in the activation of signaling pathway. It has 
been reported that several factors determined this pro-
cess, including c-Src, Lyn and Yes [18, 19]. Those factors 
can phosphorylate the different tyrosine sites, includ-
ing Tyr 845, Tyr 992, Tyr1101 and Tyr 1173 [20, 21]. 
However, no direct evidence showed that these tyros-
ine sites were involved in the cell survival and radia-
tion resistance. Apart from the above listed studies, 
the other important site for EGFR phosphorylation 
was threonine. Different from the function of tyros-
ine residues in EGFR, threonine at 654 was shown 
to be critical in nuclear transport and DNA damage 
repair in irradiated human cancer cells [16, 22]. 
Our results are consistent with data obtained in these 
studies. However, we still did not know which factor 
controls the phosphorylation at T654. Other reports 
showed that this process resulted from the activation 
of PKCe and modulation of other kinase activity [23]. 
The underlying mechanism of T654 phosphorylation 
in irradiated cervical cancer cells need to be further 
investigated. 
The other interesting finding in this work is that 
inhibition in EGFR nuclear transport led to the de-
crease in p-DNA-PK-T2609 level, showing that the 
ability of DNA repair in irradiated HeLa cells was to 
some extent impaired. Phosphorylation of DNA-PK is 
responsible for the activation of DNA-PK [24]. Thus, 
this process is critical to repair the double strand DNA 
breaks. Due to the lower expression level of p-DNA- 
-PK, the survival rate of irradiated cancer cells should 
decrease and the ability to form the tumor should 
be impaired. This is exactly what we observed in our 
study. More work could be focused on which critical 
signaling pathway(s) regulated cell death in tumor 
cells exposed to irradiation besides the EGFR signal-
ing elucidated by Dittmann et al. [22, 25]. The potential 
related signaling include beta-catenin/TCF4 [26], vas-
cular endothelial growth factor (VEGF) signaling [27], 
and downstreaming p44/42 and Akt signaling. All 
these signals are still not well-elucidated in cervical 
tumors treated by radiation. Also, the underlying 
mechanism of G0 arrest is worth to be studied, taking 
into the consideration that G0 arrest was accompanied 
by the inhibition of EGFR nuclear translocation. This 
may suggest an inhibitory effect on non-homologous 
end-joining DNA-repair (NHEJ), the predominant 
repair mechanism for DNA-double strand breaks 
[28, 29]. Understanding these mechanisms will help 
in finding more specific targets to the cervical cancer 
therapy. 
In summary, this study provides basic evidence 
that EGFR could be a potential target to the cervical 
cancer treatment.
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